Viracta Therapeutics (NASDAQ:VIRX) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Viracta Therapeutics (NASDAQ:VIRX) in a research note released on Tuesday, Benzinga reports. They currently have a $4.00 price target on the stock.

Viracta Therapeutics Stock Down 8.4 %

Shares of Viracta Therapeutics stock opened at $0.71 on Tuesday. Viracta Therapeutics has a 52-week low of $0.43 and a 52-week high of $2.38. The company has a 50 day moving average of $0.89 and a 200 day moving average of $0.70. The company has a market capitalization of $28.07 million, a P/E ratio of -0.54 and a beta of 0.93.

Viracta Therapeutics (NASDAQ:VIRX) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.05). As a group, research analysts anticipate that Viracta Therapeutics will post -1.28 earnings per share for the current fiscal year.

Institutional Trading of Viracta Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VIRX. Virtu Financial LLC acquired a new stake in Viracta Therapeutics during the fourth quarter worth approximately $29,000. Jane Street Group LLC acquired a new stake in Viracta Therapeutics during the fourth quarter worth approximately $35,000. Bank of America Corp DE raised its holdings in Viracta Therapeutics by 81.3% during the first quarter. Bank of America Corp DE now owns 23,241 shares of the company’s stock worth $37,000 after purchasing an additional 10,422 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Viracta Therapeutics during the second quarter worth approximately $52,000. Finally, Two Sigma Investments LP acquired a new stake in Viracta Therapeutics during the fourth quarter worth approximately $87,000. Institutional investors and hedge funds own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.